(Bloomberg) -- Bloomberg Markets with Carol Massar and Cory Johnson.

GUEST:
Asthika Goonewardene
Senior Analyst:Biotech
Bloomberg Intelligence
Discussing Gilead Sciences Inc. agreed to buy Kite Pharma Inc. for about $11.9 billion, making one of its biggest deals ever to expand beyond its eroding hepatitis C drug franchise. 

<p>(Bloomberg) -- Bloomberg Markets with Carol Massar and Cory Johnson.

GUEST:
Asthika Goonewardene
Senior Analyst:Biotech
Bloomberg Intelligence
Discussing Gilead Sciences Inc. agreed to buy Kite Pharma Inc. for about $11.9 billion, making one of its biggest deals ever to expand beyond its eroding hepatitis C drug franchise. </p>

Listen for reporting from the magazine that helps global leaders stay ahead. Hosts Carol Massar and Tim Stenovec cover the changing world of money, power and technology. You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET: http://bit.ly/3vTiACF. 

<p>Listen for reporting from the magazine that helps global leaders stay ahead. Hosts Carol Massar and Tim Stenovec cover the changing world of money, power and technology.&nbsp;You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET:&nbsp;<a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.&nbsp;</p>

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Bloomberg Businessweek

Bloomberg Markets: Gilead to Buy Kite for $11.9 Billion

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/a7389a12-8e86-4169-989c-ae2b00e2bfb6/transcript